Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial.
Authors
Karyn A. Goodman
Mount Sinai Department of Radiation Oncology, New York, NY;
Karyn A. Goodman , Michael J. Pishvaian , Charles D. Lopez , Kenneth Meredith , Emmanuel E. Zervos , Hassan Hatoum , Ki Y. Chung , Alex Tsobanoudis , Daniel James Berg , Antonio Ucar , Reza Nazemzadeh , Thor Johnson , Nainesh Parikh , Brian Kouri , Christopher Laing , Brian A. Boone , Imtiaz Qureshi , Ramtin Agah , Amer H. Zureikat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03257033
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 713)
DOI
10.1200/JCO.2023.41.4_suppl.713
Abstract #
713
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study.
First Author: Michael J. Pishvaian
Poster
2013 Gastrointestinal Cancers Symposium
Efficacy and feasibility of chemotherapy and radiation therapy for borderline resectable pancreatic cancer in elderly patients.
First Author: Nicholas Figura
Poster
2018 Gastrointestinal Cancers Symposium
Trans-intra-arterial gemcitabine versus continuation of IV gemcitabine and nab-paclitaxel following radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC).
First Author: Michael J. Pishvaian
Poster
2023 ASCO Annual Meeting
Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.
First Author: Hani M. Babiker